Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Irinotecan, an analog of camptothecin, which is an inhibitor of topoisomerase I, is currently used in the treatment of metastatic colorectal cancer. Camptothecin derivatives have been demonstrated to exert radiosensitizing effects on several types of cancer cells. However, to date, at least to the best of our knowledge, few studies have examined these effects in colorectal cancer cell lines. In the present study, we examined the radiosensitizing effects of irinotecan on the p53-mutant colorectal cancer cell lines, HT29 and SW620, and explored the potential underlying mechanisms. Drug cytotoxicity tests revealed that the 24 h half-maximal inhibitory concentrations (IC50s) of irinotecan as a single agent were 39.84 µg/ml (HT29 95% CI, 38.27-41.48) and 96.86 µg/ml (SW620 95% CI, 89.04-105.4); finally, concentrations <2 µg/ml were used in the subsequent experiments. Clonogenic assays revealed that irinotecan exerted radiosensitizing effects on the HT29 and SW620 cells, and the sensitivity enhancement ratios (SERs) at 2 Gy increased with increasing concentrations (SER at 2 Gy, 1.41 for the HT29 cells, 1.87 for the SW620 cells; with irinotecan at 2 µg/ml). Subsequently, the cells were divided into 4 groups: The control group, irinotecan group, radiation group and combination group. Compared with the control, irinotecan and radiation groups, the combination group had the slowest cell growth rate and the most obvious foci of Ser139p‑γH2AX. Combined treatment resulted in a firstly decreased and then increased M phase arrest and led to the most significant G2/M phase arrest, followed by the most significant increase in apoptosis. The results of western blot analysis indicated that the expression levels of proteins related to the DNA damage response system (Ser1981p‑ATM, Ser345p‑Chk1, Thr68p‑Chk2 and Ser139p‑γH2AX) and the cell cycle (Tyr15p‑Cdc2 and cyclin B1) exhibited the greatest increase in the combined group. In addition, the expression of Ser216p‑Cdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM/Chk/Cdc25C/Cdc2 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4911 · Cited by 763
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Rödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Bhonde, M. R., Hanski, M.-L., Notter, M., Gillissen, B. F., Daniel, P. T., Zeitz, M., & Hanski, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209017 · Cited by 47
Kaku, Y., Tsuchiya, A., Kanno, T., & Nishizaki, T. (2015) · Pharmacology · doi:10.1159/000381029 · Cited by 20
Cited by
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., Bruce, J. P., Wintersinger, J. A., Singh Mer, A., Lo, E. B. L., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.018 · Cited by 495
“Consistent with previous reports of the effect of CPT-11 on tumor cells (Kaku et al., 2015; Wang et al., 2018), we found that CPT-11 induced a stall in S and G2/M phases of the cell cycle and a decrease in the G1 fraction (Figure 5E).”
ResultSelf-citationIrinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1483 · Cited by 34
Metadata
- Authors
- Wang, Y., Yang, L., Zhang, J., Zhou, M., Shen, L., Deng, W., Liang, L., Hu, R., Yang, W., Yao, Y., Zhang, H., & Zhang, Z.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2018-08-03
- Volume
- 53
- Issue
- 4
- Pages
- 1667-1680
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2886848322
- Cited by
- 40
- References
- 6
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. https://app.cochat.ai/papers/10.3892/ijo.2018.4514
- The paper
- Wang, Y., Yang, L., Zhang, J., Zhou, M., Shen, L., Deng, W., Liang, L., Hu, R., Yang, W., Yao, Y., Zhang, H., & Zhang, Z. (2018). Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. International Journal of Oncology. https://doi.org/10.3892/ijo.2018.4514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.